CagriSema beats tirzepatide on weight loss in late-stage diabetes trial
The head-to-head result pits Novo Nordisk's cagrilintide-semaglutide combination against Eli Lilly's dual agonist in patients with type 2 diabetes.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 21 10:11 ETSource: Pharmaceutical Executive
The wire
- 01Novo Nordisk's CagriSema produced greater weight loss than Eli Lilly's tirzepatide in a late-stage trial in people with type 2 diabetes, according to the report.
- 02A direct comparison against the current market leader would shape prescribing and payer decisions if CagriSema reaches approval.
- 03Full trial data, glycemic endpoints and tolerability figures have not been detailed here; the result is reported secondhand and awaits peer-reviewed publication.
From the source
Read at pharmexec.comCagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
